
“OS Therapies: A Comprehensive Corporate Update”
OS Therapies Provides Corporate Update Amid Positive Clinical Data New York—(BUSINESS WIRE)—OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focusing on immunotherapies and targeted drug conjugates for cancer treatment, has announced a corporate update to showcase recent positive clinical data and corporate and financial developments. Significant Milestone in Company History According to Paul Romness,…